Lifesci Capital Issues Pessimistic Outlook for CNTX Earnings

Context Therapeutics Inc. (NASDAQ:CNTX) – Stock analysts at Lifesci Capital reduced their Q1 2026 earnings estimates for Context Therapeutics in a research note issued on Tuesday, March 24th. Lifesci Capital analyst C. Zhu now forecasts that the company will earn ($0.14) per share for the quarter, down from their previous estimate of ($0.13). Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Context Therapeutics’ current full-year earnings is ($0.51) per share. Lifesci Capital also issued estimates for Context Therapeutics’ Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.19) EPS and FY2026 earnings at ($0.62) EPS.

Several other equities research analysts have also recently issued reports on the company. JonesTrading started coverage on Context Therapeutics in a research note on Monday, December 22nd. They issued a “buy” rating and a $7.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Context Therapeutics in a research note on Wednesday, January 21st. Guggenheim reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Context Therapeutics in a report on Tuesday. Wall Street Zen upgraded Context Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Finally, D. Boral Capital reissued a “buy” rating and set a $9.00 target price on shares of Context Therapeutics in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $6.60.

Context Therapeutics Stock Up 2.0%

Shares of NASDAQ:CNTX opened at $2.59 on Friday. Context Therapeutics has a 12-month low of $0.49 and a 12-month high of $3.62. The company’s 50 day moving average price is $2.48 and its two-hundred day moving average price is $1.63. The firm has a market cap of $237.97 million, a PE ratio of -6.82 and a beta of 1.96.

Context Therapeutics (NASDAQ:CNTX) last issued its quarterly earnings data on Monday, March 23rd. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.03).

Institutional Trading of Context Therapeutics

Several large investors have recently made changes to their positions in CNTX. Virtu Financial LLC acquired a new position in Context Therapeutics during the fourth quarter valued at approximately $43,000. Quadrature Capital Ltd acquired a new stake in shares of Context Therapeutics in the 4th quarter valued at $68,000. Clear Harbor Asset Management LLC boosted its holdings in shares of Context Therapeutics by 60.5% in the 3rd quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock valued at $90,000 after purchasing an additional 35,000 shares in the last quarter. XTX Topco Ltd increased its stake in shares of Context Therapeutics by 858.8% in the 4th quarter. XTX Topco Ltd now owns 101,605 shares of the company’s stock valued at $149,000 after purchasing an additional 91,008 shares during the last quarter. Finally, Citadel Advisors LLC bought a new position in shares of Context Therapeutics in the 3rd quarter valued at $100,000. Institutional investors and hedge funds own 14.03% of the company’s stock.

Key Headlines Impacting Context Therapeutics

Here are the key news stories impacting Context Therapeutics this week:

• Positive Sentiment: Piper Sandler raised its price target, reflecting stronger upside expectations; this can boost investor sentiment and buying interest. Piper Sandler Raises Context Therapeutics Price Target
• Positive Sentiment: Guggenheim published a Buy rating on CNTX, another institutional endorsement that may support the rally. Guggenheim Buy Rating
• Positive Sentiment: D. Boral Capital issued a Buy rating, adding to the cluster of favorable analyst recommendations. D. Boral Capital Buy Rating
• Positive Sentiment: MSN reports a 13.33% increase in a published price target to $5.78, signaling bullish revision of fair value that can attract momentum traders. Price Target Increased to $5.78
• Negative Sentiment: Lifesci Capital cut multiple 2026 quarterly and full‑year EPS estimates (Q1–Q4 2026 and FY2026 now seen at about ($0.62) vs prior ~$($0.55)); the firm still carries a “Strong‑Buy” rating, but lowered earnings guidance increases short‑term downside risk if fundamentals or cash burn concerns persist.
• Negative Sentiment: HC Wainwright also trimmed Q1–Q4 2026 and multi‑year EPS forecasts (FY2026 lowered to ~$($0.60) from ~$($0.49) and later‑year estimates reduced), signaling analysts expect heavier near‑term losses than previously modeled — a negative for valuation and longer‑term profitability expectations.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.